Shorted
Cellmid logo
CDY

Cellmid

Short interest
0.02%
−0.07 pp 30d
as of 8 Dec 2017
Reported shorts
13.3K
Shares on issue
53.423M

Cellmid (CDY) company profile

Profile, insiders and operations

Company

AI-generated research profile of Cellmid

Life Sciences
Biotechnology
Pharmaceuticals
Cancer Therapy
Drug Development

Cellmid is an Australian life sciences company primarily focused on developing and commercialising innovative therapies for cancer and inflammatory diseases, with its lead drug candidate being midkine. While historically involved in consumer health products, the company is currently divesting these assets to concentrate on its midkine therapeutic pipeline. Its unique value proposition lies in targeting midkine, a novel therapeutic target with potential applications across multiple disease areas.

Director trades

19 trades recorded

DateDirectorTypeSharesPriceValue
2026-02-27Unknown Director
buy
---
2026-02-26Alexander Beard
buy
2,850,000$0.007$19,990.75
2025-05-22Unknown Director
buy
---
2025-05-21Unknown Director
buy
---
2025-05-16Alexander Beard
buy
55,564$0.006$336.32
2025-05-16Alexander Beard
buy
55,564$0.006$336.32
2025-05-15Unknown Director
buy
---
2025-05-14Alexander Beard
buy
226,881$0.006$1,373.27
2025-05-09Unknown Director
buy
---
2025-05-08Alexander Beard
buy
2,963,488$0.007$21,964.57
2025-05-07Unknown Director
buy
---
2025-05-05Alexander Beard
buy
1,734,067$0.007$12,924.4
2024-05-20Unknown Director
buy
---
2024-05-13Unknown Director
buy
---
2024-04-16Phillip Christopher
buy
1,875,000$0.016$30,000
2024-03-13Beard
buy
---
2024-03-11Alexander Beard
buy
66,133$991.990$65,603,274.67
2024-03-11Beard
buy
---
2024-03-08Alexander Beard
buy
1,148,967$0.015$16,676.12

CDY intelligence dossier

Public-source evidence for this company, with industry drill-up links.

  • Tax paid and taxable income records
  • Government contracts and public money
  • Emissions and trade exposure
  • Political donations and lobbying links
Sign in to unlock the dossierFree account · no card required